NextCure Court & Legal Update
NextCure filed a petition under Section 205 of the Delaware General Corporation Law seeking to validate a 1-for-12 reverse stock split previously implemented in July 2025. The company is seeking court validation due to uncertainty regarding the voting standard used for the split's approval in light of recent DGCL amendments and its pending merger with Avere Therapeutics. A court hearing on the validation petition is scheduled for November 6, 2026.
- Counterparty
- Delaware Court of Chancery